Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia

Cancer

Volumn 116, Issue 9, 2010, Pages 2180-2187

  Kay, Neil E ^a   Wu, Wenting ^a   Kabat, Brian ^a   LaPlant, Betsy ^a   Lin, Thomas S ^b   Byrd, John C ^b   Jelinek, Diane F ^a   Grever, Michael R ^b   Zent, Clive S ^a   Call, Timothy G ^a   Shanafelt, Tait D ^a  

^a MAYO CLINIC   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

B cell chronic lymphocytic leukemia; Chemoimmunotherapy; Cyclophosphamide; Pentostatin; Response rates; Rituximab

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; PENTOSTATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRONCHITIS; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEMOLYSIS; HUMAN; HYPOTENSION; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; URINE RETENTION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PENTOSTATIN; TREATMENT OUTCOME;

EID: 77951456080     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25028     Document Type: Article

References (23)

1. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23: 4079-4088. (Pubitemid 46211313)
2. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6-114.
3. Kay NE, Shanafelt TD, Byrd JC, Grever MR. Community-based phase II trial of PCR for CLL/SLL patients. Cancer Biother Radiopharm. 2007;22:713-714; author reply 715-717.
4. Tam CS, Keating MJ. Chemoimmunotherapy of chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007; 20:479-498.
5. Ferrajoli A, O'Brien S, Wierda W, et al. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk Lymphoma. 2005;46:S86.
6. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975-980.
7. Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007;109:2291-2298. (Pubitemid 46801560)
8. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997. (Pubitemid 26189840)
9. Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia. 2007;21:1885-1891.
10. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001;98:29-35.
11. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457-481.
12. Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia. 2002;16:993-1007. (Pubitemid 34618838)
13. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25:793-798. (Pubitemid 350002879)
14. Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol. 2001;114:342-348. (Pubitemid 32762233)
15. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230-239. (Pubitemid 47069536)
16. Hallek M, Fingerle-Rowson G, Fink AM, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL) [abstract]. Blood. 2008;112:125. Abstract 325.
17. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27: 498-503.
18. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49:49-56. (Pubitemid 351146882)
19. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5616-5623.
20. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia [see comments]. N Engl J Med. 2000; 343:1750-1757.
21. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine versus chlorambucil as first-line treatment in B cell chronic lymphocytic leukemia: an updated analysis from an international phase III study. Blood. 2008;112:728. Abstract 2091.
22. Chen C, Paul H, Xu W, et al. A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL). Blood. 2008;112:23. Abstract 44.
23. Ferrajoli A, O'Brien S, Wierda W, et al. Lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia (CLL). Blood. 2008;112:23. Abstract 45.